The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.

An immunotherapy method of targeted chemokine and cytokine delivery by a mesenchymal stem cell that expresses an immunostimulatory factor. The immunostimulatory factor is selected from the following group: CCL3, CCL19, CCL21, XCL1, CXCL9, OX40L, 4-1BBL, GITRL, CD40L, or a combination thereof. At a tumor site, the mesenchymal stem cell specifically attracts and activates an immune cell that kills tumor tissue, and the mesenchymal stem cell has a synergistic effect with chemokines and/or cytokines, having an immunotherapeutic effect with higher efficiency and few side effects, and a significantly enhanced ability to kill tumor tissue, especially colorectal cancer cells.

There is provided with a method of treating cancer. A chemokine is administered in combination with performing a hyperthermia on the cancer. This improves an effect of the hyperthermia on the cancer. Performing the hyperthermia includes locally heating the cancer.

The present invention relates to cyclic chemerin-9 derivatives of general formula (I) as described and defined herein, methods of preparing said peptides, and the use of said compounds for the treatment or prophylaxis of diseases, in particular cancer, diabetes, obesity and inflammatory disorders.

Methods of treating a subject suffering from COVID-19 are provided. Aspects of the methods including administering to the subject an effective amount of an inhibitor of CCR5/CCL5 interaction, such as a CCR5 antagonist. Also provided are methods of assessing severity of a disease involving hypercytokinemia, such as COVID-19, by determining the level of CCL5/RANTES in a subject, as well as compositions for use in such methods.

Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.

The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.

Disclosed are pharmaceutical or cosmetic compositions comprising secretomes, for example secreted proteins from stem cells, and uses thereof. A composition that contains a secretome and an acceptable excipient may be free of a cell. The compositions are useful for inducing an immune response, treating an inflammatory response, treating a microbial infection, differentiating cells, wound healing, embryonic development, placental development, central nervous system development, or morphogenesis.

A vaccinia virus into which a therapeutic gene has been introduced as an exogenous gene and a therapeutic composition containing the same. The vaccinia virus contains at least one immune regulating gene as an exogenous gene.

The present invention relates to methods and pharmaceutical compositions for the treatment of tissue lesions. The inventors showed that CCR2 is expressed on FMCs, especially on a subpopulation of progenitor cells, that they call “fetal myeloid progenitor cells” (FMPCs), and mediates the recruitment of these cells to maternal wound tissue. Moreover, the inventors reported that recruited FMCs/FMPCs improve maternal skin wound healing by organizing blood vessel endothelium and secreting pro-angiogenesis peptides, particularly chemokine CXCL1, to enhance angiogenesis in wound. In particular, the present invention relates to CCR2 agonists for use in the treatment of tissue lesions in a subject in need thereof.